- Conditions
- Stroke, Acute
- Interventions
- Nerinetide (NA-1), 2.6 mg/kg, Placebo
- Drug
- Lead sponsor
- NoNO Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 20
- States / cities
- Los Angeles, California • San Francisco, California • Torrance, California + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 46
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Vestibulopathy
- Interventions
- electrical vestibular stimulation (EVS), Sham Comparator
- Device
- Lead sponsor
- Neursantys Inc
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Cupertino, California • Menlo Park, California
- Conditions
- Amyotrophic Lateral Sclerosis, Motor Neuron Disease
- Interventions
- Not listed
- Lead sponsor
- University of Alberta
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2026
- U.S. locations
- 2
- States / cities
- Miami, Florida • Salt Lake City, Utah
- Conditions
- Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
- Interventions
- Infusion of 200% maintenance fluids as balanced crystalloid IV solution, Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
- Other
- Lead sponsor
- University of Calgary
- Other
- Eligibility
- 9 Months to 21 Years
- Enrollment
- 1,040 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more
- Conditions
- Tetraplegia, Spinal Cord Injuries, Quadriplegia Flaccid
- Interventions
- Surgery/Occupational Therapy
- Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 7
- States / cities
- Stanford, California • Miami, Florida • Ann Arbor, Michigan + 4 more
- Conditions
- Stroke
- Interventions
- IV rt-PA alone, endovascular therapy
- Drug · Other
- Lead sponsor
- Joseph Broderick
- Other
- Eligibility
- 18 Years to 82 Years
- Enrollment
- 656 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 39 more
- Conditions
- Pregnancy Related, Venous Thromboembolism
- Interventions
- Not listed
- Lead sponsor
- University of Calgary
- Other
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 825 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Elbow Fracture, Elbow Injury, Elbow Dislocation
- Interventions
- Lactose Placebo, Ketotifen Fumarate 2mg, Ketotifen Fumarate 5mg
- Drug
- Lead sponsor
- University of Calgary
- Other
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 395 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Charlotte, North Carolina • Burlington, Vermont
- Conditions
- Transient Ischemic Attack, Stroke
- Interventions
- Aspirin, Clopidogrel, Simvastatin
- Drug
- Lead sponsor
- University of Calgary
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Urinary Incontinence, Overactive Bladder Syndrome, Overactive Bladder, Urologic Diseases
- Interventions
- OnabotulinumtoxinA
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 89 Years · Male only
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Hepatitis C, Chronic Hepatitis B
- Interventions
- Regression of fibrosis, Specific risk factors related to hepatocellular carcinoma
- Other
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 2
- States / cities
- Little Rock, Arkansas • Chapel Hill, North Carolina
- Conditions
- Knee Dislocations, Multiple Ligament Knee Injuries
- Interventions
- Early Surgery, Delayed Surgery, Early Rehab, Delayed Rehab
- Procedure
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 16 Years to 55 Years
- Enrollment
- 690 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Diabetic Polyneuropathy, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetes Complications
- Interventions
- Exposure: Corneal nerve fibre morphology by the CCM Procedure
- Other
- Lead sponsor
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 624 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Diabetic Nephropathies, Coronary Artery Disease
- Interventions
- Allopurinol, Placebo
- Drug
- Lead sponsor
- Alessandro Doria
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 23
- States / cities
- Aurora, Colorado • Denver, Colorado • Atlanta, Georgia + 15 more
- Conditions
- Cardiac Allograft Vasculopathy
- Interventions
- Perflutren Lipid Microsphere, RTMPE
- Drug · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Bipolar Disorder
- Interventions
- MCN36 (nutritional supplement), Placebo
- Drug
- Lead sponsor
- University of Calgary
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension, PAH WHO Group I
- Interventions
- Sitaxsentan, Bosentan, Ambrisentan
- Drug
- Lead sponsor
- West Penn Allegheny Health System
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis
- Interventions
- Methotrexate, Sulfasalazine, Leflunomide, Pamidronate, Zoledronic acid, Etanercept, Adalimumab, Certolizumab, Infliximab, Golimumab, NSAID
- Drug
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2050
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Sarcoma, Giant Cell Tumor of Bone
- Interventions
- Surgery
- Procedure
- Lead sponsor
- University of Calgary
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Rochester, Minnesota
- Conditions
- Intracerebral Hemorrhage
- Interventions
- Deferoxamine Mesylate, Placebo (for Deferoxamine Mesylate)
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Palo Alto, California • San Francisco, California + 18 more
- Conditions
- Intracerebral Hemorrhage
- Interventions
- Deferoxamine, Normal saline
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Palo Alto, California • San Francisco, California + 19 more
- Conditions
- Breast Cancer, Liquid Biopsy, Early Detection
- Interventions
- Not listed
- Lead sponsor
- Syantra Inc.
- Industry
- Eligibility
- 30 Years to 75 Years · Female only
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • New York, New York
- Conditions
- Retinopathy of Prematurity
- Interventions
- Not listed
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 32 Weeks to 40 Weeks
- Enrollment
- 269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 11
- States / cities
- Louisville, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 8 more
- Conditions
- Pelvic Floor Dysfunction
- Interventions
- paper form, web/smartphone form
- Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 4
- States / cities
- Fayetteville, Arkansas • New York, New York • Houston, Texas + 1 more